Cochlear Ltd (ASX: COH) Share Price and News

Price

$272.85

Movement

0.54 (+0.2%)

as at 13 Jun - Closed (20 mins delayed)

52 Week Range

$246.14 - $350.31

 
1 Year Return

-16.47%

Cochlear Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $17.81 billion
P/E Ratio 47.71
Dividend Yield 1.58%
Shares Outstanding 65.40 million
Earnings per share 5.650
Dividend per share 4.30
Year To Date Return -6.27%
Earnings Yield 2.10%
Franking 80
Share Price

$272.85

Day Change

0.54 (+0.2%)

52 Week Range

$246.14 - $350.31

Yesterday's Close

$272.31

Today's Open

$271.73

Days Range

$265.32 - $275.74

Volume

320,490

Avg. Volume (1 month)

172,284

Turnover

$87,426,670

as at 13 Jun - Closed

  • Cochlear Ltd (ASX: COH)
    Latest News

    a woman
    Investing

    Cochlear Limited surges 5%: What shareholders need to know

    Cochlear Limited (ASX:COH) bounces back above $80, but investors are confused…

    Read more »

    a woman
    Investing

    3 of my favourite growth stocks: Oil Search Limited, Amcor Limited and Cochlear Limited

    These 3 stocks could be worth buying ahead of improved financial performance: Oil Search Limited (ASX:OSH), Amcor Limited (ASX:AMC) and…

    Read more »

    a woman
    Investing

    Does FlexiGroup Limited offer growth at a discount?

    Buying undervalued companies including FlexiGroup Limited (ASX:FXL) and companies operating offshore including Cochlear Limited (ASX:COH) will improve your investment returns.

    Read more »

    a woman
    Investing

    Will the RBA cut interest rates tomorrow? Here's how to profit either way

    Long term investing in quality companies including CSL Limited (ASX:CSL) and Cochlear Limited (ASX:COH) can help you beat the volatility…

    Read more »

    a woman
    Investing

    10 blue chip stocks to buy before Tuesday's rate cut

    Amcor Limited (ASX:AMC) and Computershare Limited (ASX:CPU) are in prime position to surge higher.

    Read more »

    Investing

    Is it time to sell Cochlear Limited?

    Cochlear Limited (ASX: COH) and ResMed Inc. (CHESS) (ASX: RMD) will always be the sector's best loved stocks but this…

    Read more »

    a woman
    Investing

    3 top healthcare stocks for your watch list

    I’m waiting for the market to offer me bargain prices for these three stocks.

    Read more »

    a woman
    Investing

    Cochlear Limited jumps on court ruling: Here's what you need to know

    Implantable hearing device manufacturer, Cochlear Limited (ASX:COH), has seen its shares jump on news a US District Court ruled in…

    Read more »

    a woman
    Investing

    Do you have the personality traits to help you become a better investor?

    Find out how to improve your investing power and learn why Cochlear Limited (ASX:COH) is a strong growth stock for…

    Read more »

    a woman
    Investing

    3 healthcare stocks going gangbusters

    ResMed Inc. (CHESS) (ASX:RMD), Capitol Health Ltd (ASX:CAJ) and Cochlear Limited (ASX:COH) have soared above the S&P/ASX200 (ASX:XJO) (Index:^AXJO) over…

    Read more »

    a woman
    Investing

    Here's why you should own CSL Limited and Cochlear Limited as the Aussie dollar falls

    International healthcare companies like CSL Limited (ASX:CSL) and Cochlear Limited (ASX:COH) can get an earnings boost from a weaker Aussie…

    Read more »

    a woman
    Investing

    CSL Limited has strong lead over Commonwealth Bank of Australia in race to $100

    Who will be first to see $100 share price? CSL Limited (ASX: CSL) or Commonwealth Bank of Australia (ASX:CBA)?

    Read more »

    Frequently Asked Questions

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    20 Mar 2025 $2.1500 80.00% Interim 14 Apr 2025
    17 Sep 2024 $2.1000 80.00% Final 10 Oct 2024
    21 Mar 2024 $2.0000 70.00% Interim 15 Apr 2024
    18 Sep 2023 $1.7500 70.00% Final 11 Oct 2023
    21 Mar 2023 $1.5500 35.00% Interim 14 Apr 2023
    21 Sep 2022 $1.4500 40.00% Final 17 Oct 2022
    28 Mar 2022 $1.5500 0.00% Interim 21 Apr 2022
    23 Sep 2021 $1.4000 0.00% Final 18 Oct 2021
    25 Mar 2021 $1.1500 0.00% Interim 20 Apr 2021
    19 Sep 2019 $1.7500 100.00% Final 14 Oct 2019
    25 Mar 2019 $1.5500 100.00% Interim 16 Apr 2019
    17 Sep 2018 $1.6000 100.00% Final 10 Oct 2018
    19 Mar 2018 $1.4000 100.00% Interim 12 Apr 2018
    19 Sep 2017 $1.0000 100.00% Final 11 Oct 2017
    15 Mar 2017 $1.3000 100.00% Interim 06 Apr 2017
    07 Sep 2016 $1.2000 100.00% Final 29 Sep 2016
    10 Mar 2016 $1.1000 100.00% Interim 01 Apr 2016
    02 Sep 2014 $1.2700 20.00% Final 25 Sep 2014
    20 Feb 2006 $0.4500 100.00% Interim 14 Mar 2006
    26 Aug 2005 $0.4500 100.00% Final 22 Sep 2005
    19 Feb 2004 $0.3500 100.00% Interim 17 Mar 2004

    COH ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    12th Jun 2025 2025-06-12T08:30:38 Cochlear launches new cochlear implant systemYesNo8:30am3219k
    12th Jun 2025 2025-06-12T08:23:33 Cochlear provides update to FY25 earnings guidanceYesNo8:23am1147k
    10th Jun 2025 2025-06-10T17:09:14 Change of registry addressYesNo5:09pm1130k
    19th May 2025 2025-05-19T17:16:53 Change in substantial holdingYesNo5:16pm12299k
    29th Apr 2025 2025-04-29T10:55:47 Application for quotation of securities - COHYesNo10:55am718k
    11th Apr 2025 2025-04-11T15:12:22 Notification of cessation of securities - COHYesNo3:12pm413k
    11th Apr 2025 2025-04-11T08:44:05 Notification regarding unquoted securities - COHYesNo8:44am616k
    8th Apr 2025 2025-04-08T09:47:51 Cochlear statement on US tariff announcementYesNo9:47am1132k
    3rd Apr 2025 2025-04-03T09:37:08 Cochlear awaits clarification on application of US tariffYesNo9:37am1132k
    24th Mar 2025 2025-03-24T09:04:31 Update - Dividend/Distribution - COHYesNo9:04am516k

    About Cochlear Ltd

    Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.

    The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.

    Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.

    Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.

     

    COH Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    11 Jun 2025 $270.46 $0.91 0.34% 131,969 $269.94 $273.73 $269.00
    10 Jun 2025 $269.55 $1.06 0.39% 196,549 $268.84 $271.66 $265.73
    06 Jun 2025 $268.49 $-2.78 -1.02% 170,082 $274.00 $274.44 $267.38
    05 Jun 2025 $271.27 $1.42 0.53% 164,377 $272.22 $274.96 $269.18
    04 Jun 2025 $269.85 $1.50 0.56% 166,934 $266.76 $270.81 $266.53
    03 Jun 2025 $268.35 $-3.38 -1.24% 137,390 $270.24 $272.35 $268.01
    02 Jun 2025 $271.73 $0.23 0.08% 140,133 $268.00 $272.74 $268.00
    30 May 2025 $271.50 $1.50 0.56% 422,563 $269.91 $272.87 $267.74
    29 May 2025 $270.00 $-1.51 -0.56% 112,104 $271.48 $273.98 $268.87
    28 May 2025 $271.51 $-1.17 -0.43% 97,583 $273.13 $274.29 $270.99
    27 May 2025 $272.68 $2.93 1.09% 110,397 $272.32 $273.12 $269.52
    26 May 2025 $269.75 $1.39 0.52% 106,374 $267.00 $271.67 $265.96
    23 May 2025 $268.36 $-1.48 -0.55% 173,139 $270.34 $271.49 $267.33
    22 May 2025 $269.84 $-2.48 -0.91% 153,074 $268.49 $273.75 $267.23
    21 May 2025 $272.32 $-1.75 -0.64% 208,604 $276.15 $276.62 $272.11
    20 May 2025 $274.07 $3.00 1.11% 115,961 $272.92 $275.81 $270.61
    19 May 2025 $271.07 $2.69 1.00% 128,274 $268.87 $271.07 $267.73
    16 May 2025 $268.38 $1.52 0.57% 106,952 $269.23 $270.53 $267.06
    15 May 2025 $266.86 $1.93 0.73% 254,761 $266.65 $269.70 $265.50
    14 May 2025 $264.93 $-4.13 -1.53% 131,893 $268.01 $268.99 $264.87
    13 May 2025 $269.06 $3.26 1.23% 140,261 $267.89 $273.63 $266.56

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    28 Feb 2025 Christine McLoughlin Buy 200 $52,346
    On-market trade.
    13 Nov 2024 Dig Howitt Issued 4,309 $1,279,471
    Issue of securities. 27,333 rights
    13 Nov 2024 Dig Howitt Issued 13,445 $3,992,223
    Issue of options.
    30 Oct 2024 Dig Howitt Sell 10,982 $3,132,072
    On-market trade.
    29 Oct 2024 Dig Howitt Buy 11,000 $2,266,660
    Exercise of options.
    29 Oct 2024 Dig Howitt Exercise 11,000 $2,266,660
    Exercise of options.
    23 Sep 2024 Dig Howitt Issued 3,082 $862,620
    Issue of securities. 23,024 Rights
    13 Sep 2024 Dig Howitt Exercise 2,314 $476,822
    Exercise of options.
    13 Sep 2024 Dig Howitt Sell 2,314 $668,560
    On-market trade.
    13 Sep 2024 Dig Howitt Buy 2,314 $476,822
    Exercise of options.
    12 Sep 2024 Dig Howitt Buy 5,000 $1,030,300
    Exercise of options.
    12 Sep 2024 Dig Howitt Sell 5,000 $1,452,900
    On-market trade.
    12 Sep 2024 Dig Howitt Exercise 5,000 $1,030,300
    Exercise of options.
    29 Aug 2024 Karen Penrose Buy 100 $29,834
    On-market trade.
    26 Aug 2024 Michael del Prado Buy 95 $19,855
    On-market trade. US $
    22 Aug 2024 Christine McLoughlin Buy 250 $76,392
    On-market trade.
    21 Aug 2024 Karen Penrose Buy 49 $14,894
    On-market trade.
    20 Aug 2024 Karen Penrose Buy 48 $14,978
    On-market trade.
    16 Aug 2024 Dig Howitt Issued 7,384 $2,256,255
    Conversion of securities.
    16 Aug 2024 Dig Howitt Exercise 18,314 $5,596,025
    Exercise of options.
    16 Aug 2024 Dig Howitt Expiry 2,903 $887,040
    Options expired.
    16 Aug 2024 Dig Howitt Issued 18,314 $5,596,025
    Issue of options.
    16 Aug 2024 Dig Howitt Expiry 655 $200,141
    As advised by the company. 27,326 Rights, lapsed
    16 Aug 2024 Dig Howitt Exercise 7,384 $2,256,255
    Conversion of securities. 19,942 Rights

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Ms Christine Frances McLoughlin Non-Executive Director Nov 2020
    Ms McLoughlin has experience as a director on the boards of ASX Top 50 Companies in financial services (including banking, life insurance, superannuation, asset management and general insurance), resources, health insurance and infrastructure sectors over the past 14 years. Other boards are Chairman of the Suncorp Group Limited. Co-founder and Chairman of the Minerva Network. Former directorships include Chairman and Director of Venues NSW and Chairman of Destination NSW. Director, nib Holding Limited, Whitehaven Coal Limited, Spark Infrastructure, the McGrath Foundation and more recently the Chancellor of the University of Wollongong. She is Chair of the People and Culture Committee and member of the Risk and Product and Services Innovation Committee.
    Mr Michael Grenfell Daniell Non-Executive Director Jan 2020
    Mr Daniell has over 40 years of experience in the medical device industry with executive leadership experience. He is Former Managing Director and CEO of Fisher & Paykel Healthcare Corporation Limited responsible for the global business and operations including the design, manufacture and marketing of products and systems for use in respiratory care, acute care and the treatment of obstructive sleep apnea. Other directorships are Director of Fisher & Paykel Healthcare Corporation Ltd; Director, Tait International Limited; Director, Medical Research Commercialisation Fund. Former directorships include Advisory Board Chair, Te Titoki Mataora (NZ). He is Chair of the Product and Services Innovation Committee and member of the Risk and Medical Science Committee.
    Ms Catriona Alison Deans Non-Executive DirectorNon-Executive Chairman Jan 2015
    Ms Deans has experience leading technology enabled businesses across e-commerce, media and financial services. Deans was former Chief Executive Officer of netus, Hoyts Cinemas, ecorp and eBay Australia and New Zealand. Other directorships include Director of Ramsay Health Care Limited, Calix Limited, Deputy Group Pty Ltd and Fitness Passport Pty Ltd. Director of The Observership Program. Former directorships include SCEGGS Darlinghurst Limited, Westpac Banking Corporation, Insurance Australia Group Limited and Social Ventures Australia. She was former Member of AICD Corporate Governance Committee.
    Ms Karen Lee Collett Penrose Non-Executive Director Jul 2022
    Ms Penrose has executive career in senior leadership and Chief Financial Officer roles in financial services. She is a company director, having served on the boards of a number of ASX100 companies and experienced across health care, financial services, property and infrastructure industries. Other boards include Director, Ramsay Health Care Limited, Bank of Queensland Limited and Reece Limited. Director, Ramsay General De Sante (associated with Karen's directorship of Ramsay Health Care Limited), Marshall Investments Pty Limited, NSW Waratahs Ltd and Waratahs Rugby Pty Ltd. Former directorships are Vicinity Centres, Estia Health Ltd, Rugby Australia Limited. She is Chair of the Risk Committee and member of the People and Culture and Product and Services Innovation Committee.
    Mr Glen Francis Boreham Non-Executive Director Jan 2015
    Mr Boreham Led organisations in information technology, new media and the creative industries through periods of rapid change and innovation. He is Former Managing Director of IBM Australia and New Zealand. Other boards include Strategic Advisor, IXUP. Former directorships were held with Southern Cross Media Group, Data#3 and Link Group. Chairman of Screen Australia, Advance (Global Australian Network), Business School and Industry Advisory Board for the University of Technology, Sydney and Advisory Board IXUP. he is member of the Risk Committee, People and Culture and Product and Services Innovation Committees.
    Professor Bruce Gregory Robinson Non-Executive Director Dec 2016
    Mr Robinson has over 20 years of leadership experience as an academic physician/scientist across research, healthcare and medicine, and tertiary education. He is Co-Head of the Cancer Genetics Laboratory at the Kolling Institute for Medical Research and Chair of Research, North Sydney Local Health District. He is Former Dean of The University of Sydney's Sydney Medical School and Head of Medicine at Sydney's Royal North Shore Hospital. Other boards are Director, MaynePharma, QBiotics, Ecofibre and EOF BIO LLC (associated with the Ecofibre directorship). Deputy Chairman (former Chairman), Hoc Mai Foundation. Senior Advisor to McKinsey & Company and Advisor to MinterEllison. Former directorships include Chairman of National Health and Medical Research Council; chairman of Medical Benefits Schedule Review Taskforce; Director, Lorica Health Pty Limited, Firefly and Digital Health Agency CRC and Woolcock Institute of Medical Research. He is Chair of Medical Science Committee and member of the Product and Services Innovation Committees.
    Mr Dig Howitt PresidentChief Executive OfficerManaging Director Jul 2017
    Mr Howitt has experience across the Company in roles including Chief Operating Officer, President, Asia Pacific and SVP, Manufacturing and Logistics. Prior to joining Cochlear he worked for Boston Consulting Group and held a General Management role at Boral. Dig is a member of the Champions of Change Coalition, STEM group. He is member of the Medical Science and Product and Services Innovation Committees.
    Mr Michael del Prado Non-Executive Director Jan 2022
    Mr Prado has over 34 years of global experience in the medical device and pharmaceutical industries with senior executive leadership roles in Johnson & Johnson medical device businesses in the US, Asia-Pac and EMEA. He is Former Company Group Chairman of Ethicon, a surgical company. Other boards are Ambu A/S. Former directorships include Co-lead Director of Verb Surgical. Advisory Board, Singapore Management University Lee Kong Chian School of Business. He is member of the Medical Science, People and Culture and Product and Services Innovation Committee.
    Ms Caroline Louise Clarke Non-Executive Director Sep 2024
    Ms Clarke has more than 30 years of commercial experience, including 20 years of executive roles at medical devices, medical equipment and healthcare services businesses in large global companies. Ms Clarke was most recently CEO and Executive Vice President ASEAN Pacific for Philips . Ms Clarke will become a member of the People and Culture Committee, the Product & Services Innovation Committee .
    Ms Kristy Jo Company Secretary Apr 2024
    -
    Mr Rob McGrory Company Secretary Apr 2024
    -
    Stu Sayers Chief Financial Officer
    -
    Jan Janssen Chief Technology Officer
    -
    Kristy Jo Company Secretary
    -
    Rob McGrory Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    HSBC Custody Nominees (Australia) Limited i 28,724,005 43.86%
    J P Morgan Nominees Australia Pty Limited 10,419,733 15.91%
    Citicorp Nominees Pty Limited 7,185,958 10.97%
    National Nominees Limited 1,260,072 1.92%
    BNP Paribas Noms Pty Ltd 1,248,618 1.91%
    BNP Paribas Nominees Pty Ltd <Agency Lending A/C> 1,234,623 1.89%
    HSBC Custody Nominees (Australia) Limited <Ntcomnwlth Super Corp A/C> 473,902 0.72%
    Australian Foundation Investment Company Limited 324,174 0.49%
    Netwealth Investments Limited <Wrap Services A/C> 322,512 0.49%
    BNP Paribas Nominees Pty Ltd <Hub24 Custodial Serv Ltd> 311,198 0.48%
    Citicorp Nominees Pty Limited <Colonial First State Inv A/C> 257,130 0.39%
    HSBC Custody Nominees (Australia) Limited Gsco Eca 250,716 0.38%
    Mr Christopher Graham Roberts 172,387 0.26%
    HSBC Custody Nominees (Australia) Limited A/C 2 166,930 0.25%
    Custodial Services Limited <Beneficiaries Holding A/C> 148,099 0.23%
    HSBC Custody Nominees (Australia) Limited ii 146,653 0.22%
    BNP Paribas Nominees Pty Ltd <Clearstream> 131,365 0.20%
    HSBC Custody Nominees (Australia) Limited <Euroclear Bank Sa Nv A/C> 125,730 0.19%
    Ubs Nominees Pty Ltd 95,069 0.15%
    Ioof Investment Services Limited <Ips Superfund A/C> 72,784 0.11%

    Profile

    since

    Note